anti-CD33 CAR gamma delta T-cell therapy (TC BioPharm/University College London)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD33 CAR gamma delta T-cell therapy (TC BioPharm/University College London)
Drug Alias Nameanti-CD33 CAR T-cell therapy (TC BioPharm/University College London)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity College LondonTc Biopharm Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A